Mallinckrodt plc to Report Fourth Quarter and Fiscal Year 2024 Financial Results
Mallinckrodt has scheduled the release of its fourth quarter and fiscal year 2024 financial results for Tuesday, March 11, 2025. The global specialty pharmaceutical company will host an investor conference call at 8:00 a.m. ET on the same day. Participants can access the call through registration links provided, with options including an audio-only webcast and replay availability through the company's Investor Relations webpage.
Mallinckrodt ha programmato il rilascio dei risultati finanziari per il quarto trimestre e l'anno fiscale 2024 per martedì 11 marzo 2025. La società farmaceutica globale specializzata ospiterà una conferenza telefonica per gli investitori alle 8:00 a.m. ET lo stesso giorno. I partecipanti possono accedere alla chiamata tramite i link di registrazione forniti, con opzioni che includono un webcast audio e la disponibilità di una registrazione tramite la pagina web delle Relazioni con gli Investitori della società.
Mallinckrodt ha programado la publicación de sus resultados financieros del cuarto trimestre y del año fiscal 2024 para el martes 11 de marzo de 2025. La compañía farmacéutica especializada a nivel global llevará a cabo una conferencia telefónica para inversores a las 8:00 a.m. ET el mismo día. Los participantes pueden acceder a la llamada a través de los enlaces de registro proporcionados, con opciones que incluyen un webcast solo de audio y la disponibilidad de una repetición a través de la página web de Relaciones con Inversores de la compañía.
말린크로트는 2024 회계연도 및 4분기 재무 결과 발표를 2025년 3월 11일 화요일로 예정했습니다. 이 글로벌 전문 제약회사는 같은 날 오전 8시 ET에 투자자 컨퍼런스 콜을 개최할 예정입니다. 참가자는 제공된 등록 링크를 통해 전화를 접속할 수 있으며, 오디오 전용 웹캐스트 및 회사의 투자자 관계 웹페이지를 통한 재생 가능성 옵션이 포함되어 있습니다.
Mallinckrodt a prévu la publication de ses résultats financiers pour le quatrième trimestre et l'exercice 2024 pour le mardi 11 mars 2025. La société pharmaceutique spécialisée à l'échelle mondiale organisera une conférence téléphonique pour les investisseurs à 8h00 ET le même jour. Les participants peuvent accéder à l'appel via les liens d'inscription fournis, avec des options comprenant un webinaire audio uniquement et la disponibilité d'une rediffusion sur la page des Relations Investisseurs de l'entreprise.
Mallinckrodt hat die Veröffentlichung seiner Finanzergebnisse für das vierte Quartal und das Geschäftsjahr 2024 für Dienstag, den 11. März 2025 angesetzt. Das globale Spezialpharmaunternehmen wird am selben Tag um 8:00 Uhr ET eine Telefonkonferenz für Investoren abhalten. Teilnehmer können über die bereitgestellten Registrierungslinks auf den Anruf zugreifen, wobei Optionen wie ein nur Audio-Webcast und die Verfügbarkeit einer Wiederholung über die Investor Relations-Webseite des Unternehmens angeboten werden.
- None.
- None.
A conference call for investors will begin at 8:00 a.m. ET and can be accessed as follows:
- Live Call Participant Registration (including dial-in): https://register.vevent.com/register/BIf17087938ddc47079bf48d6d5e7c5687
- Audio Only Webcast Link (live and replay): https://edge.media-server.com/mmc/p/igfp4swa
- On the Investor Relations page of the Mallinckrodt website: https://ir.mallinckrodt.com/
ABOUT MALLINCKRODT
Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The Company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, and ophthalmology; neonatal respiratory critical care therapies; and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the Company in advance of or in lieu of distributing a press release or a filing with the
Investor Relations Contact
Derek Belz
Vice President, Investor Relations
314-654-3950
derek.belz@mnk.com
Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. © 2025.
View original content to download multimedia:https://www.prnewswire.com/news-releases/mallinckrodt-plc-to-report-fourth-quarter-and-fiscal-year-2024-financial-results-302387746.html
SOURCE Mallinckrodt plc
FAQ
When will Mallinckrodt (MNK) release Q4 and FY 2024 earnings?
What time is Mallinckrodt's (MNK) Q4 2024 earnings call?
How can investors access Mallinckrodt's (MNK) Q4 2024 earnings call?
Will there be a replay available for Mallinckrodt's (MNK) Q4 2024 earnings call?
